While CD56+ Vδ2 T cells have greater anti-tumor effector function compared with their CD56- counterparts, the opposite is observed of Vδ1 T cells for which positive expression of CD56 is associated with lower anti-tumor potency. Here, NCAM1 is linked to neoplasm.